Hybio Pharmaceutical Co Ltd
300199
Company Profile
Business description
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
Contact
4th Floor, Office Building, Hanyu Biomedical Park
Middle District, High-tech Industrial Park
Nanshan District
Guangdong Province
Shenzhen518057
CHNT: +86 75526588000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,035
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.30 | 48.10 | -0.53% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 25,929.45 | 233.79 | -0.89% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 58,952.11 | 633.75 | -1.06% |
| NZX 50 Index | 12,908.15 | 37.45 | -0.29% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,768.00 | 51.50 | -0.58% |
| SSE Composite Index | 4,096.41 | 9.85 | -0.24% |